Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series A | Alive

Total Raised


Last Raised

$19M | 2 yrs ago

About Artms Products

ARTMS Products is focused on the development and commercialization of technologies and products that enable cyclotron production of needed radioisotopes.

Artms Products Headquarters Location

4250 Wesbrook Mall

Vancouver, British Columbia, V6T 1W5,



Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Artms Products News

ARTMS Announces New Appointments to Executive Leadership Team

Sep 2, 2020

Company adds experienced executives to support the continued expansion of commercial activities and focus on radiopharmaceutical innovator and manufacturer relationships | Source: ARTMS Products Inc. VANCOUVER, British Columbia, Sept. 02, 2020 (GLOBE NEWSWIRE) -- ARTMS Inc. (ARTMS), the global leader in the development and commercialization of technologies that are transforming the production of the world’s most-used diagnostic imaging isotopes, today announced that it has expanded its senior management team with the addition of two industry veterans, Doug Gentilcore as Chief Commercial Officer and Mark Przekop as Vice President of Marketing and Business Development. Doug will develop and lead ARTMS’ overall commercial strategy while Mark will be responsible for developing business partners and leading all customer-focused activities. “I am pleased to welcome Doug Gentilcore and Mark Przekop to ARTMS. Having worked with both Doug and Mark in the past I am confident that they will provide additional expertise to the outstanding leadership team currently at ARTMS,” said Mr. Charles S. Conroy, CEO of ARTMS. “Both Doug and Mark have extensive experience in leading radiopharmaceutical commercialization and operations.” Doug joins ARTMS from Implerem, LLC, a strategic consulting firm focused in the healthcare space where he was founder and president. Prior to Implerem, Doug was the Vice President of Global Sales and Business Operations at Jubilant Radiopharma. Over his tenure, Doug grew their radiopharmaceutical programs nearly 10-fold. Prior to Jubilant, Doug held sales positions of increasing responsibility at Purview, GE Healthcare and Pfizer. Mark brings over 30 years of experience in the radiopharmacy industry including Vice President sales and operational roles at Jubilant and leadership positions within GE Healthcare, Nycomed Amersham and Mallinckrodt. “ARTMS’ executive team is accelerating the commercialization and global adoption of our radiopharmaceutical production platform, the QUANTM Irradiation SystemTM (QISTM) ” added Mr. Conroy. “In the few short months since completion of our US$19M Series A financing , ARTMS has advanced a number of partnerships and collaboration initiatives to move ARMTS’ proprietary products and services forward. At this moment ARTMS has made considerable progress towards achieving our mission of making high-value medical isotopes such as gallium-68 (68Ga), zirconium-89 (89Zr), technetium‐99m (99mTc) and copper-64 (64Cu) more readily available to clinicians and researchers at cancer centers and universities, biotech companies and pharmaceutical drug innovators across the globe, thereby making innovative and important diagnostic imaging agents accessible to more patients than ever before.” ARTMS has a rich pipeline of exciting products for medical isotope production for a variety of disease indications and recently announced collaborations with TELIX Pharmaceuticals and ImaginAb . ARTMS continues to pursue additional opportunities for collaboration and partnering activities on a global basis. Media Contact About ARTMS Based in Vancouver, British Columbia, Canada, ARTMS Inc. is a global leader in the development of novel technologies and products which enable the high-quality and high-yield production of the world’s most-used diagnostic imaging isotopes. ARTMS’ flagship product, the QUANTM Irradiation SystemTM (QISTM), enables decentralized, cost-effective, large-scale production of important medical isotopes such as gallium-68 (68Ga), zirconium-89 (89Zr), technetium‐99m (99mTc) and copper-64 (64Cu) using local, hospital-based medical cyclotrons empowering the user to control their supply chain. ARTMS commercializes these award-winning and proprietary Canadian inventions on a global basis and has the prospect of revolutionizing the nuclear medicine industry. For more information on the QUANTM Irradiation System™ and ARTMS, please follow us on Twitter  @Quantm99  and  LinkedIn  and visit Related Articles

  • When was Artms Products founded?

    Artms Products was founded in 2013.

  • Where is Artms Products's headquarters?

    Artms Products's headquarters is located at 4250 Wesbrook Mall, Vancouver.

  • What is Artms Products's latest funding round?

    Artms Products's latest funding round is Series A.

  • How much did Artms Products raise?

    Artms Products raised a total of $23.13M.

  • Who are the investors of Artms Products?

    Investors of Artms Products include Quark Venture, GF Securities, Deerfield Management and Western Economic Diversification Canada.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.